Emergence of quinolone-resistant escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin

Clinical Infectious Diseases

Volumn 20, Issue 3, 1995, Pages 557-560

  Carratalá, Jordi ^a   Fernández Sevilla, Alberto ^a   Tubau, Fe ^a   Callis, Manuel ^a   Gudiol, Francesc ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AZTREONAM; CEFTAZIDIME; CIPROFLOXACIN; CORTICOSTEROID; CYTOTOXIC AGENT; IMIPENEM; NORFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ARTICLE; BACTEREMIA; CANCER PATIENT; CELLULITIS; CLINICAL ARTICLE; ESCHERICHIA COLI; FEMALE; HUMAN; MALE; MINIMUM INHIBITORY CONCENTRATION; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PNEUMONIA; PRIORITY JOURNAL; RISK FACTOR; URINARY TRACT INFECTION;

ADULT; AGED; AGED, 80 AND OVER; BACTEREMIA; DRUG RESISTANCE, MICROBIAL; ESCHERICHIA COLI INFECTIONS; FEMALE; HUMAN; INCIDENCE; MALE; MIDDLE AGE; NEOPLASMS; NEUTROPENIA; NORFLOXACIN; RETROSPECTIVE STUDIES; RISK FACTORS; SUPPORT, NON-U.S. GOV'T;

EID: 0028986117     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/clinids/20.3.557     Document Type: Article

References (22)

1. Bodey GP. Antimicrobial prophylaxis for infection in neutropenic patients. CurrClin Top Infect Dis 1988;9:1-43.
2. Schimpf TSC, Greene WH. Young VM. et al. Infection prevention in acute nonlymphocytic leukemia: laminar air flow room reverse isolation with oral, nonabsorbable antibiotic prophylaxis. Ann Intern Med 1975;82:351-8.
3. Wade JC, Schimpff SC, Hargadon MT. Fortner CL. Young VM, Wier- nik PH. A comparison of trimethoprim-sulfamethoxazole plus nystatin with gentamicin plus nystatin in the prevention of infections in acute leukemia. N Engl J Med 1981;304:1057-62.
4. Wilson JM, Guiney DG. Failure of oral trimethoprim-sulfamethoxazole prophylaxis in acute leukemia: isolation of resistant plasmids from strains of enterobacteriaceae causing bacteremia. N Engl J Med 1982;306:16-20.
5. Ward TT, Thomas RG, Fye CL, et al. Trimethropim-sulfamethoxazole prophylaxis in granulocytopenic patients with acute leukemia: evaluation of serum antibiotic levels in a randomized, double-blind, placebo-controlled Department of Veterans Affairs cooperative study. Clin Infect Dis 1993; 17:323-32.
6. Hooper DC, Wolfson JS. Norfloxacin, ciprofloxacin, and ofloxacin: current clinical roles. Curr Clin Top Infect Dis 1989; 10:194-240.
7. Karp JE, Merz WG. Hendricksen C, et al. Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia: a randomized, double-blind, placebo- controlled trial. Ann Intern Med 1987; 106:1-7.
8. Dekker AW. Rozenberg-Arska M, Verhoef J. Infection prophylaxis in acute leukemia: a comparison of ciprofloxacin with trimethoprim- sulfamethoxazole and colistin. Ann Intern Med 1987; 106:7-12.
9. The GIMEMA Infection Program. Prevention of bacterial infection in neutropenic patients with hematologic malignancies: a randomized, multicenter trial comparing norfloxacin with ciprofloxacin. Ann Intern Med 1991; 115:7-12.
10. Talbot GH. Cassileth PA. Paradiso L, Correa-Coronas R, Bond L. The Enoxacin Prophylaxis Study Group. Oral enoxacin for infection prevention in adults with acute nonlymphocytic leukemia. Antimicrob Agents Chemother 1993;37:474-82.
11. Winston DJ, Ho WG, Bruckner DA, Gale RP, Champlin RE. Ofloxacin versus vancomycin/polymyxin for prevention of infections in granulocytopenic patients. Am J Med 1990;88:36-42.
12. Donnelly JP, Maschmeyer G, Daenen S. Selective oral antimicrobial prophylaxis for the prevention of infection in acute leukaemia—ciprofloxacin versus co-trimoxazole plus colistin. The EORTC-Gnoto- biotic Project Group. Eur J Cancer 1992;28A:873-8.
13. Classen DC, Burke JP, Ford CD, et al. Streptococcus mitis sepsis in bone marrow transplant patients receiving oral antimicrobial prophylaxis. Am J Med 1990;89:441-6.
14. Young LS. The new fluorinated quinolones for infection prevention in acute leukemia [editorial]. Ann Intern Med 1987; 106:144-6.
15. Bow EJ, Ronald AR. Antibacterial chemoprophylaxis in neutropenic patients—where do we go from here? [editorial]. Clin Infect Dis 1993;17:333-7.
16. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. NCCLS document M100-S4. Villanova, Pennsylvania: National Committee for Clinical Laboratory Standards, 1992.
17. Aguiar JM, Chacon J, Canton R, Baquero F. The emergence of highly fluoroquinolone-resistant Escherichia coliin community-acquired urinary tract infections [letter], J Antimicrob Chemother 1992; 29: 349-50.
18. Perez-Trallero E, Urbieta M, Jimenez D, Garcla-Arenzana JM, Cilia G. Ten-year survey of quinolone resistance in Escherichia coli causing urinary tract infections. Eur J Clin Microbiol Infect Dis 1993;12:349-51.
19. Muder RR, Brennen C, Goetz AM, Wagener MM, Rihs JD. Association with prior fluoroquinolone therapy of widespread ciprofloxacin resistance among gram-negative isolates in a Veterans Affairs medical center. Antimicrob Agents Chemother 1991;35:256-8.
20. Lopez-Brea M, Alarcon T. Isolation of fluoroquinolone-resistant Escherichia coli and Klebsiella pneumoniae from an infected Hickman catheter. Eur J Clin Microbiol Infect Dis 1990;9:345-7.
21. Kern WV, Markus A, Andriof E. Bacteremia due to fluoroquinolone- resistant Escherichia coli in two immunocompromised patients. Eur J Clin Microbiol Infect Dis 1994; 13:161-5.
22. Jonsson M. Walder M. Forsgren A. First clinical isolate of highly fluoroquinolone-resistant Escherichia coli in Scandinavia [letter], Eur J Clin Microbiol Infect Dis 1990;9:851-3.